FDA Investigator Rafeeq A Habeeb

Rafeeq A Habeeb has conducted inspections on 63 sites in 5 countries as of 14 May 2024. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
63
Last Inspection Date:
14 May 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America, India, Mexico, Canada, China
FDA Investigators that have inspected at least one site in common with Rafeeq A Habeeb:
Abby E Pelletier, Abdollah Koolivand, Alan L Truong, Alan P Kurtzberg, Alanna L Mussawwir Bias, Amina Bashir, Amy S Graf, Ana P Pineda Zavaleta, Andrace L Deyampert, Andrea D Swingle, Andrew J Barrowcliff, Andrew Le, Angela E Glenn, Anna M Brannen, Anthony J Ladner, Anthony R Petriella, Ariel Cruz Figueroa, Ava M Bowman, Azza Talaat, Bailey A Uetrecht, Barbara D Bennett, Bei Y He, Benjamin J Smith, Bernard P Heidt, Beverley A Phillips, Brandi N Mcgrady, Brett R Havranek, Brian J Davis, Brian M Campbell, Brian P Hendrickson, Brian R Yaun, Byungja E Marciante, Calvin K Cook, Carl A Huffman, III, Carl J Montgomery, Carla A Norris, Charles E Frelix, Charles I Ann, Charles L Zhou, Charles M Spyr, Charles Yuanchia Kuo, PhD, Chelsea J Falkowski, Chris A Sack, Christi L Bellmore, Christian L Witkovskie, Christopher S Keating, Christopher T Middendorf, Claire M Minden, Concepcion Cruz, Jr, Constantin Y Philopoulos, Corrine M Carter, Cristina Ausin Moreno, PhD, Daniel J Gorski, Daniel J Roberts, Danny Tuntevski, David A Oluwo, David A Paterson, David J Eide, David P Moorhead, Debara R Reese, Debara Reese, Denise L Burosh, Dennis E Guilfoyle, PhD, Dennis R Downer, Diane L Raccasi, Dina A Tallman, Dipesh K Shah, Doan T Nguyen, PharmD, Donald C Obenhuber, PhD, Donald W Myrick, Donna K Speer, Eboni S Funderburk, Edwardstine J Reese, Edwin Jao, Elisa A Nickum, Elizabeth Ll Edwards, Elizabeth P Kinsella, Emest F Bizjak, Emilie E Kahn, Emily J Orban, Enrico Joset Mangahis, Eric E Joneson, Eric S Pittman, Erin M Miller, Esther C Broner, PhD, Felix Maldonado, Frederick M Lochner, Gam S Zamil, Guerda Prophete, Guo Q Shen, Hans T Meyers, Helen B Ricalde, Hugh M Mcclure, II, Hyung Yul Lee, Ifueko Osemwota, Jacob G Lutz, James A Lane, James E Frye, James L Finn, James N Rench, Jamie L Dion, Jean Blackston Hill, Jeffery A Hangartner, Jeffrey A Sommers, Jeffrey D Meng, Jennifer A Kemp, Jennifer L Gustavus, Jennifer L Johnson, Jennifer R Johnson, John N Woodall, Jon P Antoniou, José E Meléndez, Joseph A Piechocki, Joseph R Strelnik, Joshua M Adams, Joshua P Wireman, Joslyn K Brunelle, PhD, Joy Rkozlowski Klena, Julia A Avery, Karen M Montgomery (KMM), Katherine Szestypalow, Kathleen D Culver, Kathryn G Brown, Kelley L Clark, Kellia N Hicks, Kenneth H Williams, Kham Phommachanh, Kristina Nastovski, L'oreal F Walker, Larry K Austin, Laura Fontan, MS, Lauren E Sexton, Lauren Iacono Connors, PhD, Lauren N Howard, LCDR Sean Byrd, Leigh Anne Myers, Linda M Cheny, Lindsey M Schwierjohann, Lisa L Flores, Lisa M Bellows, Lisa R Hilliar, Lisa Shin, Logan T Williams, Lori A Gioia, Luella J Rossi, Luis A Dasta, Lynnsey A Renn, Mancia R Walker, Marcellinus D Dordunoo, Margaret M Annes, Margaret N Persich, Maria Cruz Fisher, Marianela Aponte Cruz, Maribeth G Grattan, Maribeth G Niesen, Mark E Parmon, Marlon K Turner, Martin R Vowell, Massoud Motamed, Matthew B Casale, Matthew R Sleeter, Meisha R Sampson, Meisha Waters, Melina Lrodriguez Upton, Mercy Oyugi, Michael A Charles, Michael E Clark, Michael P Sheehan, Michael Shanks, MS, Michele L Forster, PhD, Michele L Obert, Michele Perry Williams, Michelle L Jones, Misty D Harvey, Montgomery Montgomery, Karen M, Muna Algharibeh, Myra K Casey, Nadeem I Chaudhry, Nailing Zhang, Natalie A Mickelsen, DVM, Nathan B Davis, Nayan J Patel, Neal D Singletary, PhD, Neali H Lucas, Nicholas L Hunt, Nicholas L Paulin, Nicole E Knowlton, Nicole S Williams, Omotunde O Osunsanmi, Pablo Alcantara, Paranthaman Senthamaraikannan, Parul M Patel, Patricia A Cochran, Patricia H Dlugosz, Patrick B Cummings, Patsy J Domingo, Paula P Demichael, Qiao Y Bobo, Rabia Ballica, PhD, Rafael Nevarez Nieves, Rasha Bamieh, Raymond T Oji, Reba A Gates, Rebecca E Dombrowski, Rebecca Rodriguez, Rita K Kabaso, Robert Barbosa, Robert D Tollefsen, Robert G Taylor, Robert J Ham, Robert M Barbosa, Roy C Stephens, Samuel W Labinjo, Sandra A Boyd, Sargum C Sood, Scott B Laufenberg, Scott R Nichols, PhD, Shannon A Gregory, Shirley J Berryman, Sixto M Mercado Rios, Sneha S Patel, Stephen D Brown, Steven P Eastham, Susan F Laska, MS, Susan P Bruederle, Susanna E Ford, Suyang Qin, Talmane J Fisher, Tamayo C Barnes, Tamil Arasu, PhD, Tara G Bizjak, Tenzin Jangchup, Teresa I Navas, Theodore N Sietsema, Thomas J Arista, Thuy T Nguyen, LCDR, Tiara Nbrown Crosen, Timothy J Schmidt, Tina M Pawlowski, Tomika L Bivens, Tonnie L Carter, Tracey L Siebesma, Tracy K Li, Travis V Hull, Vaishali J Patel, Vesa Vuniqi, Vickie J Kanion, Vidya B Pai, Vlada Matusovsky, Wayne E Seifert, Wen Ning Chan (Sally), Wendy G Tan, PhD, William A Warnick, William D Tingley, Yangmin Ning, Yanming An, PhD, Yuan Chia Kuo, Yumi J Hiramine, Zachary L Miller, Zachary L Stamm

Rafeeq A Habeeb's Documents

Publish Date Document Type Title
February, 2023 EIR Jubilant HollisterStier General Partnership - EIR, 2023-11-01
May, 2023 FDA 483 Megafine Pharma (P) Limited - Form 483, 2023-05-12
November, 2022 FDA 483 SRIKAR LABORATORIES PRIVATE LIMITED - Form 483, 2022-11-10
August, 2022 FDA 483 Lambda Research Inc - Form 483, 2022-08-26
May, 2022 FDA 483 Degasa, S.A. de C.V. - Form 483, 2022-05-27
March, 2022 FDA 483 Camco Chemicals Company Inc - Form 483, 2022-03-02
March, 2021 FDA 483 Eli Lilly and Company - Form 483, 2021-03-16
March, 2024 FDA 483 KP Pharmaceutical Technology, Inc. - Form 483, 2024-03-21
September, 2021 FDA 483 SnugZ/USA, LLC - Form 483, 2021-09-17
June, 2021 FDA 483 Response Allergan Sales, LLC - Form 483R, 2021-07-15
September, 2021 FDA 483 Response Yusef Manufacturing Laboratories, LLC - Form 483R, 2021-10-12
June, 2021 EIR Allergan Sales, LLC - EIR, 2021-06-24
March, 2021 FDA 483 Response Eli Lilly and Company - Form 483R, 2021-04-06
November, 2023 FDA 483 Catalent Indiana, LLC - Form 483, 2023-11-15
August, 2022 FDA 483 Glenfin Chemicals Private Ltd. - Form 483, 2022-08-19
June, 2023 FDA 483 Aeropres Corp - Form 483, 2023-06-27
August, 2022 FDA 483 Jyoti Simple Solutions Private Limited - Form 483, 2022-08-11
October, 2022 FDA 483 Haney, Inc. - Form 483, 2022-10-18
September, 2021 FDA 483 Yusef Manufacturing Laboratories, LLC - Form 483, 2021-09-24
December, 2023 FDA 483 ZYDUS LIFESCIENCES LIMITED - Form 483, 2023-12-22
January, 2023 FDA 483 Response Piramal Pharma Solutions Inc. - Form 483R, 2023-01-25
June, 2021 FDA 483 Allergan Sales, LLC - Form 483, 2021-06-24
January, 2023 FDA 483 Piramal Pharma Solutions Inc. - Form 483, 2023-01-10
December, 2023 FDA 483 LAURUS SYNTHESIS PRIVATE LIMITED - Form 483, 2023-12-12
May, 2022 FDA 483 Boehringer Ingelheim Promeco S.A. de C.V. - Form 483, 2022-05-20
February, 2023 FDA 483 KP Pharmaceutical Technology, Inc. - Form 483, 2023-02-03
August, 2021 FDA 483 Univar Solutions USA Inc. - Form 483, 2021-08-25
February, 2023 FDA 483 Jubilant HollisterStier General Partnership - Form 483, 2023-02-28
May, 2024 FDA 483 Thorn BioScience - Form 483, 2024-05-22
July, 2024 FDA 483 Upsher-Smith Laboratories, LLC - Form 483, 2024-07-11
February, 2024 FDA 483 The Gorilla Glue Company - Form 483, 2024-02-23

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more